Navigation Links
Cerulean Pharma's Lead Candidate Selected as a "Top 10 Oncology Project to Watch"
Date:11/19/2012

CAMBRIDGE, Mass., Nov. 19, 2012 /PRNewswire/ -- Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that its lead candidate, CRLX101, was named as one of the "Top 10 Oncology Projects to Watch" by an independent panel of experts convened by Elsevier Business Intelligence and the Campbell Alliance.

The panel selected compounds using various criteria, including market size and medical need, development history, supporting science, potential for expansion beyond the initial indications and multi-level partnering opportunities.

As part of this recognition, Christopher Guiffre, senior vice president and chief business officer of Cerulean, will present the CRLX101 opportunity at Windhover's Therapeutic Area Partnerships meeting taking place on November 28 through 30, 2012, at the Westin Copley in Boston. Mr. Guiffre's presentation will occur on Thursday, November 29 at 1:40 p.m. Eastern Time.

"Cerulean's nanopharmaceuticals dynamically target tumors by entering through the large pores associated with blood vessels leading to tumors and releasing their drug inside the tumor over time," said Oliver Fetzer, Ph.D., president and chief executive officer of Cerulean. "This approach, which relies not on the patient's genetic profile but on a characteristic of blood vessels common to many tumors, allows us to evaluate CRLX101 in multiple tumor types as a monotherapy and in combination with Avastin®."

About CRLX101

CRLX101 is an investigational anti-cancer agent that is a dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1 alpha (HIF-1α). CRLX101 is designed to concentrate in tumors, prolonging drug exposure at the site of action. Significant anti-tumor activity has been observed across a wide range of cancers in animal models. CRLX101 is in Phase 2 clinical development. More information can be found at

SOURCE Cerulean Pharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
2. ePharmaSolutions Launches an Innovative Patient Recruitment Application for Windows 8
3. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
4. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
5. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
7. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
8. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
9. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
10. New Candidate Drug Stops Cancer Cells, Regenerates Nerve Cells
11. Chimerix Signs Worldwide License Agreement With Merck For CMX157, A Novel Candidate For The Treatment Of HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... -- Reportlinker.com announces that a new market research ... North America Aesthetic Lasers and Energy Devices Market ... North America Aesthetic Lasers and ... GlobalData,s new report, "North America Aesthetic Lasers ... key market data on the North America Aesthetic ...
(Date:8/28/2014)... , Aug. 28, 2014 ... research report is available in its ... and Compliance Services Industry (U.S.): Analytics, ... Forecasts to 2021, NAIC 541380 ... Testing Laboratories, Safety and ...
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces that a ... catalogue: Germany Aesthetic Lasers and Energy ... http://www.reportlinker.com/p02343442/Germany-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html Germany Aesthetic Lasers ... Summary GlobalData,s new report, "Germany Aesthetic Lasers ... key market data on the Germany Aesthetic Lasers ...
Breaking Medicine Technology:North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 2Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 3Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 4Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 5Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 6Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 9
... ATLANTA, Georgia, May 30 The International,Diabetes ... fund a lifestyle intervention trial that seeks ... type 2 diabetes in Chennai, India., ... community based diabetes prevention programme will determine,optimal ...
... children under 3 years old with diffuse,pontine glioma compared ... cancer may be distinct in young patients, MEMPHIS, ... have shown that children under 3 years old,who have ... to have a,better outcome than older children with the ...
Cached Medicine Technology:International Diabetes Federation Grant Supports Lifestyle Intervention Study to Prevent Type 2 Diabetes in India 2International Diabetes Federation Grant Supports Lifestyle Intervention Study to Prevent Type 2 Diabetes in India 3St. Jude Finds Young Age May Give Survival Advantage to Children With Certain Brain Tumors 2St. Jude Finds Young Age May Give Survival Advantage to Children With Certain Brain Tumors 3
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 Dr. Parsa ... late stages of hair loss achieve great results in hair ... Facial Hair Transplant , an FUE method that harvests ... area. This method lets patients whose hair loss classification ... Facial Hair Transplant is a great alternative for those advanced ...
(Date:8/29/2014)... La Miraca, California (PRWEB) August 29, 2014 ... clinical training to Chapman University Physical Therapy students ... students at Chapman University will be shadowing Healthpointe ... which will allow them to develop clinical experience ... University Physical Therapy students will gain insight into ...
(Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- Astronauts ... travel appears to disrupt human immune systems, a new ... on any long missions to asteroids, the moon and ... or flu while in space can be dangerous, NASA ... immune cells in the blood of International Space Station ...
(Date:8/29/2014)... Pursuing its deepest desires to help build ... stunning new design that promises to redefine the global ... surrogacy platform has witnessed a 42 percent increase in ... month, the FindSurrogateMother.com community is formed by hopeful parents ... — the precious gift of life. , Whether intended ...
(Date:8/29/2014)... Healthpointe Medical Group, one of ... center from LAXMed. The medical center is less than 2 ... west of the 405 freeway. , The LAX clinic ... LAX center is located at: 8610 S. Sepulveda Blvd., Suite ... Healthpointe LAX office will provide the same comprehensive services ...
Breaking Medicine News(10 mins):Health News:Advanced Hair Loss Patients Can Now Qualify for Hair Transplants Using Facial Donor Hair 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:Spaceflight Might Weaken Astronauts' Immune Systems 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3Health News:Healthpointe Obtains a New Medical Clinic in the LAX Area 2
... Starpharma saw an 8% increase in its share, following approval ... prevent transmission of HIV. // The company even signed ... of Allergy and Infectious Diseases, an integral part of the ... approved products for the prevention of HIV infection. The FDA ...
... balance its usage between office work and private life, as ... instructions and work during evenings and weekends //when they are ... and during office hours they find the mobile phones and ... of office time and work concentration. Most of the people ...
... soldiers for experiments for finding a vaccine for Hepatitis. ... while serving abroad. Hepatitis E is reported to account ... //In 1995, the US Armed Forces Research Institute of ... Army Institute of Research, set up a unit in ...
... the primary diseases affecting the children below two years. It ... the end of November and the incidence increases and reaches ... Lehman, MD, associate director of pediatric infectious diseases and HIV ... about the disease and this situation has to change. ...
... Population Fund, in 2005 than in any year since its ... 171.// ,In 2004, 166 nations had contributed to UNFPA. ... 2005. Contributions to the UNFPA regular resources last year were ... previous year's level of $322 million. The top six donors ...
... said China has improved its capability to handle epidemic ... SARS epidemic in 2003 exposed the flaws in China's ... comprehensive steps to address them, he said. ,After ... end of 2005, the goal of an improved and ...
Cached Medicine News:Health News:Starpharma Develops New Gel (Vivagel) To Prevent HIV Transmission 2Health News:US Reportedly Experimenting on Nepali Soldiers 2Health News:Parental Knowledge Of RSV Infections Is Vital 2Health News:Record Number of Countries Contributed to UNFPA in 2005 2
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e...
... P.M.® lets you sleep on ... in the morning awake with ... ready to take on the ... comfort and protection, this preservative-free ...
Due to its thick formula, REFRESH CELLUVISC Lubricant Eye Drops is ideal for persistent dry eye conditions. REFRESH CELLUVISC provides lasting relief and protection for dry, scratchy eyes....
ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2% is indicated for lowering IOP in patients with open-angle galucoma or ocular hypertension....
Medicine Products: